The use of SC administered rapid-acting analogs has considerably simplified the management of humans with uncomplicated DKA (patients who did not have persistent hypotension after the administration of 1 liter of normal saline, patients not in a comatose state, and those without acute myocardial ischemia, heart failure, end-stage renal disease, hepatic failure, anasarca, dementia, or pregnancy) (18, 19), proving to be similarly effective and safe when compared to IVCRI of regular insulin (18–21). The gene discussed is INS; the disease is Hepatic failure.